Drug Resistance to EGFR Inhibitors in Lung Cancer

Osamu Tetsu a, b, Matthew J. Hangauer b, Janyaporn Phuchareon a, b, David W. Eisele a, b, Frank McCormick b

a Department of Otolaryngology – Head and Neck Surgery, School of Medicine, University of California San Francisco, and b UCSF Helen Diller Family Comprehensive Cancer Center, School of Medicine, University of California San Francisco, San Francisco, Calif., USA

Key Words
Non-small-cell lung cancer · Epidermal growth factor receptor · Tyrosine kinase inhibitors · Drug resistance · Cancer dormancy · Persister cells · Monotherapy · Combination therapy · Precision medicine

Abstract
Background: The discovery of mutations in epidermal growth factor receptor (EGFR) has dramatically changed the treatment of patients with non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths worldwide [1, 2]. It is classified into 2 major histologic types based on microscopic features: small-cell lung cancer (SCLC, approx. 15%) and non-small-cell lung cancer (NSCLC, approx. 85%). Because NSCLC represents a heterogeneous group of cancers, it is further divided into 3 different pathological subtypes: adenocarcinoma (40%), squamous-cell carcinoma (25–30%) and large-cell carcinoma (10–15%) [3].

Methods: We reviewed the literature to provide an overview of the drug resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC.

Results: The mechanisms causing primary, acquired and persistent drug resistance to TKIs vary. Researchers and clinicians, who have used study findings to develop more effective therapeutic approaches, have found that the sequential use of single agents presents a formidable challenge, suggesting that multidrug combinations must be considered.

Conclusions: In the era of precision medicine, oncologists should promptly obtain an accurate diagnosis of drug resistance in each patient to be able to design the most relevant combination therapy to overcome patient-specific drug resistance.

Introduction

Lung cancer is the leading cause of cancer deaths worldwide [1, 2]. It is classified into 2 major histologic types based on microscopic features: small-cell lung cancer (SCLC, approx. 15%) and non-small-cell lung cancer (NSCLC, approx. 85%). Because NSCLC represents a heterogeneous group of cancers, it is further divided into 3 different pathological subtypes: adenocarcinoma (40%), squamous-cell carcinoma (25–30%) and large-cell carcinoma (10–15%) [3].

These pathological classifications are clinically important, as treatment decisions have depended on tumor histology [4, 5]. For example, localized NSCLC at an early stage is mainly treated with surgery followed by adjuvant chemotherapy [4]. In contrast, SCLC – even at an early stage – has rarely been treated surgically, as it tends to be more aggressive and spread more rapidly [5]. SCLC is...
thus usually treated with chemo- and radiotherapy. However, histological distinctions are no longer sufficient for determining treatment plans [6].

Molecular characterization of NSCLCs has provided valuable information for diagnosis, prognosis and treatment [6]. In fact, the discovery of mutations in epidermal growth factor receptor (EGFR) and chromosomal translocations in anaplastic lymphoma kinase (ALK) has dramatically changed the treatment of patients with lung adenocarcinoma [7]. Targeted therapies are currently approved for these abnormalities and show considerable promise [1, 2, 7]. However, drug resistance has become a substantial issue [1, 2, 8–11].

In this review article, we focus on EGFR-targeted therapy and present an overview of drug resistance in NSCLC. We also discuss therapeutic strategies designed to circumvent drug resistance to EGFR inhibitors.

Methods

A search of the literature revealed 131 articles (until November 15, 2015) relevant to drug resistance to EGFR TKIs in NSCLC.

Results

Molecular Profiling of Lung Adenocarcinomas

Recent studies have demonstrated that lung adenocarcinomas have recurrent mutations in multiple oncogenes: KRAS (32%), STK11 (17%), EGFR (11%), neurofibromin 1 (NF1, 11%), BRAF (7%), MET (7%), human epidermal growth factor receptor 2 (HER2, 3%), PTEN (3%), ROS1 (2%), ALK (1%), AKT1 (1%), RET (<1%), HRAS (<1%), NRAS (<1%), MEK1 (<1%), and PIK3CA (<1%) [12–14]. With the exception of PIK3CA [14], these mutations are mutually exclusive. Therefore, genetic profiling of NSCLC allows precise molecular classification of the disease. It can also be used to predict the potential efficacy of targeted therapy for each individual with adenocarcinoma [7, 10–13]. In fact, evaluation of gene mutations in EGFR and chromosomal rearrangements of the gene encoding ALK (most commonly resulting in an EML4-ALK fusion gene) are now considered to be the standard of care in advanced-stage pulmonary adenocarcinomas [7]. Intriguingly, EGFR mutations are more prevalent in patients with adenocarcinoma from East Asia who have never smoked or whose habit was light, whereas KRAS mutations are most frequent in Caucasian patients with adenocarcinoma in North America and Europe who have been long-time or heavy smokers [15, 16].

Oncogenic Addiction and Targeted Therapy

The genesis and progression of human cancer involves multiple genetic and epigenetic alterations [17, 18]. However, the inactivation of a single oncogene can often impair the survival of these altered cells [19]. This phenomenon known as oncogene addiction has provided a rationale for molecular-targeted therapy. The use in lung cancer of selective tyrosine kinase inhibitors (TKIs) for EGFR or ALK represents such examples [7]. Here we focus on EGFR TKIs.

EGFR is a receptor tyrosine kinase (RTK) that exists on the cell surface [20]. It belongs to the EGFR/HER family, consisting of 4 members: EGFR, HER2, HER3 and HER4. EGFR becomes activated by overexpression or by ligand-dependent or ligand-independent mechanisms. Ligand-independent activation of the receptor manifests as gain-of-function mutations with the mutant allele showing gene amplification [21, 22].

Gefitinib (Iressa) was the first agent designed to target EGFR [22, 23]. It received US Food and Drug Administration (FDA) approval for the treatment of NSCLC, yet its activity was limited to 10–20% of patients with refractory lung cancer [1, 2]. In 2002, 2 retrospective cohort studies unexpectedly revealed a correlation between dramatic clinical responses to the TKI and activating EGFR mutations in the catalytic kinase domain of EGFR [21, 22]. Almost similar observations were obtained from treatment with another EGFR TKI, erlotinib (Tarceva), which was approved by the FDA in November 2004 [2, 24–26]. Approximately 85% of EGFR mutations are either exon 19 deletions (45%) or the missense mutation L858R (an amino acid substitution at position 858 from leucine to arginine) in exon 21 (41%) within the kinase domain [27, 28].

Heterogeneous Initial Responses to EGFR TKIs in NSCLCs

A recent randomized, phase-3 clinical trial with erlotinib found tumor reduction of >90% in only 5% of patients (a complete to near-complete response [29]). The remainder achieved a partial response or maintained stable disease, even though they too had TKI-sensitive EGFR mutations. The heterogeneous nature of this primary response raised questions about its causation whether this is attributable to resistance inherent in the tumor cells or to acute drug tolerance, or both.

Primary and Acquired Drug Resistance

Drug resistance is a major obstacle to the success of targeted therapies, including EGFR TKIs [1, 2]. Based on
tumor response to the initial therapy, drug resistance is classified as either primary (also called innate or intrinsic) or acquired (adaptive or secondary) [2, 10]. Patients with primary resistance do not respond at all to treatment, while those with acquired resistance may initially respond completely or partially, only to fail to do so over time. Approximately 10% of patients harboring TKI-sensitive EGFR mutations show primary resistance to TKIs [2, 10, 29].

**Primary Drug Resistance to EGFR TKIs**

Primary resistance to EGFR TKIs in NSCLCs is mostly associated with wild-type EGFR [30]. It also develops from activated mutations in KRAS or BRAF, or loss of function of the apoptotic protein Bim or some uncommon EGFR mutation [31–34]. More recently, the tumor microenvironment or activation of NF-κB signaling has also been shown to elicit primary resistance [35–38].

**Wild-Type EGFR**

Although erlotinib can prolong survival in patients with unselected NSCLC after first- or second-line chemotherapy [39], the benefit from EGFR TKIs is small in the 90% of NSCLC patients with wild-type EGFR [30, 40]. A recent clinical trial confirmed this observation. Only 3% of patients harboring wild-type EGFR had a partial response to erlotinib; in the remainder, docetaxel (Taxotere) was more effective [41].

**KRAS and BRAF Mutations**

EGFR, KRAS and BRAF mutations are mutually exclusive [14]. In approximately 30% of NSCLCs, activating KRAS mutations are observed at codons 12 or 13 and are considered to constitute a negative predictor for EGFR-targeted therapies [31]. Despite EGFR inhibition, KRAS mutations constitutively activate downstream MAPK signaling, presenting another mechanism that contributes to primary resistance.

Likewise, 7% of NSCLCs harbor mutations in BRAF. The most common change in BRAF is the V600E mutation (an amino acid substitution at position 600 from valine to glutamic acid), which confers resistance to EGFR TKIs but shows increased sensitivity to specific small-molecule V600E inhibitors as well as to MEK inhibitors [32].

**Bim Polymorphism**

Bim is a BH3-only protein, which is essential for apoptosis and caspase induction in EGFR-mutated NSCLC cells [42–44]. Thus, a reduction of Bim expression in NSCLC may cause drug resistance to TKIs. A recent report demonstrated that genetic polymorphism generates alternative splicing variants of Bim protein lacking the BH3 domain, which is sufficient to confer primary resistance to TKIs in NSCLCs harboring EGFR mutations [33].

**Various EGFR Mutations**

The most common activating EGFR mutations (85%) are either L858R or exon 19 deletions, which confer drug sensitivity to EGFR TKIs [27, 34]. However, less common EGFR mutations also exist. Among them, G719X in exon 18 (a substitution at position 719 from glycine to glutamic acid; 3%) and L861Q in exon 21 (an amino acid substitution at position 861 from leucine to glutamic acid; 2%) appear sensitive to TKIs [27, 34]. However, not all EGFR mutations are equally sensitive [27]; some cause TKI resistance. For example, small insertions or duplications in exon 20, which account for 5–10% of EGFR mutations, are associated with primary resistance, except for the rare case with EGFR exon 20 insertion A763_Y764insFQEA [45, 46].

A recent study demonstrated that, although the vast majority of cancer cells harbor classic activating EGFR mutations, the EGFR TKI resistance conferring the T790M EGFR mutation (an amino acid substitution from threonine to methionine at position 790) can be found within rare cells in primary tumors. Subsequent clonal selection of these preexisting EGFR TKI-resistant cells during EGFR TKI treatment may contribute to drug resistance [47, 48].

**Tumor Microenvironment**

The latest studies have demonstrated that RTK ligands secreted through paracrine, autocrine and endocrine mechanisms in the tumor microenvironment are also important determinants of primary therapeutic responses to anticancer kinase inhibitors [35–37]. Indeed, hepatocyte growth factor (HGF), fibroblast growth factor (FGF) and neuregulin 1 (NRG1) confer primary drug resistance to a large number of cancer cell lines by activating RTKs and thus stimulating either the Ras/MAPK or PI3K/AKT pro-survival pathway or both [35]. HGF-mediated activation of the RTK MET is suspected as the most important cause of primary resistance to anticancer agents [35–37].

**Activation of NF-κB Signaling**

NF-κB signaling activation was recently identified as a mechanism of primary resistance to EGFR TKI [38]. Low expression of IκB, the NF-κB inhibitor, was a predictor of
a poor clinical outcome in patients treated with erlotinib [38]. Thus, combined therapy with EGFR TKI and an inhibitor of NF-κB signaling can enhance primary responses in a subset of NSCLCs harboring EGFR mutations.

**Acquired Drug Resistance to EGFR TKIs**

Acquired resistance to EGFR TKIs develops after an average of 1 year of continuous treatment [1, 2]. A clinical definition has recently been proposed by Jackman et al. [49]. According to their criteria, the tumor should harbor TKI-sensitive EGFR mutations such as L858R or exon 19 deletions, should have responded either partially or completely (unless stable disease has been present for more than 6 months) and have demonstrated systemic progression.

Four different mechanisms of acquired drug resistance to EGFR TKIs have been reported [1, 2]: (1) EGFR target alterations in the drug target itself (such as T790M secondary mutation [30, 45]), which can nullify the activity of gefitinib or erlotinib without changing the RTK activity, (2) activation of alternative signaling pathways to bypass the EGFR inhibition (such as amplification of RTK MET [50, 51] or HER2 [52, 53], activation of another oncogenic driver, BRAF [54] or inactivation of the tumor suppressors PTEN [55, 56] or NF1 [57]), (3) a lineage switch through histological transformation from NSCLC to SCLC [58–60] or epithelial-mesenchymal transition (EMT) [61–63] and (4) intratumor heterogeneity [64].

**T790M and Other Secondary EGFR Mutations**

Acquired resistance to gefitinib and erlotinib is predominantly mediated by the development of the T790M EGFR secondary mutation, which occurs in 50–65% of patients with the EGFR mutation and TKI resistance [1, 2, 8, 30, 45]. Threonine 790 is the gatekeeper residue in EGFR, lies within the ATP-binding pocket of EGFR and influences drug effectiveness [65]. In agreement with this notion, a recent report demonstrated that the T790M mutation in EGFR confers drug resistance by increasing the affinity for ATP [66]. In addition, a further chromosomal amplification of the gene locus may enhance the inhibitory effect of T790M [67].

Gatekeeper mutations can be a common mechanism of acquired drug resistance to targeted therapies in cancer [68]. In fact, analogous mutations are reported in malignancies exposed to various TKIs: imatinib-resistant T315I BCR-ABL fusion kinase in chronic myelogenous leukemia (CML) [69], imatinib-resistant T670I KIT in gastrointestinal stromal tumor (GIST) [70] and crizotinib-resistant L1196M ALK fusion gene in NSCLC [71].

Other rarer TKI-induced EGFR mutations, constituting <10% of all secondary substitutions in EGFR, have been reported: L747S [42], D761Y [72] and T854A [73]. Although these non-T790M mutations have been associated with acquired resistance to TKIs, their drug-resistant mechanism is not yet clear [74].

**Activation of Alternative Pathways**

Recently, a common mechanism of acquired resistance to EGFR TKIs has been reported as a result of an RTK switch, such as amplification of MET [50, 51] or HER2 [52, 53] or activation of HER3 [75, 76], insulin-like growth factor 1 receptor (IGF-1R) [77, 78] or fibroblast growth factor receptor 1 (FGFR1) [79, 80].

**MET Amplification.** Amplification of the MET gene is identified in 5–20% of EGFR-mutated NSCLCs with acquired drug resistance to EGFR TKIs [50]. Amplified MET specifically makes a heterodimeric complex with HER3, one of 4 members of the EGFR kinase family, and activates the PI3K/AKT pathway to bypass EGFR inhibition [50]. MET amplification is not mutually exclusive with the T790M secondary mutation; indeed, the latter is seen in 50% [51]. Thus, it is possible to conjecture that MET-amplified clones are selected after exposure to EGFR TKIs and then acquire the T790M mutation. In fact, MET amplification is found in 2–4% of previously untreated EGFR-mutated NSCLCs [51]. In any case, the population harboring activating EGFR mutations and MET amplification can achieve a clinical benefit from combined therapy with EGFR and MET inhibitors, as shown in a recent phase-III clinical trial [81].

**HER2 Amplification.** HER2 is amplified in 12% of tumors with acquired resistance, but the gene amplification is found in only 1% of untreated lung adenocarcinoma [52, 53]. No mutations in HER2 are found in this population. Importantly, HER2 amplification and T790M mutation occur in a mutually exclusive manner. These observations clearly suggest that HER2 amplification is an alternative mechanism of drug resistance to EGFR TKIs [2]. Indeed, HER2 is a potential therapeutic target because its overexpression or knockdown can confer, respectively, resistance or sensitivity to TKIs in NSCLC cells [53].

**HER3 Activation.** HER3 is activated independently of MET amplification in NSCLCs, and may contribute to acquired drug resistance to EGFR TKI [75, 76]. HER3 lacks several catalytically important residues and is thought to be an inactive pseudokinase [82]. However, it can form a heterodimeric complex with EGFR/HER2 to stimulate downstream cell signaling [83, 84] and can be
activated by its ligand NRG1 through an autocrine mechanism [85].

In NSCLC cells, HER3 couples with EGFR to activate the PI3K/AKT pathway in gefitinib-sensitive NSCLC cell lines, but not in gefitinib-resistant lines, suggesting that NRG1-bound HER3 may predominantly dimerize with RTKs other than EGFR to promote acquired resistance to TKIs [76]. This mechanism may provide a rationale for the combined treatment of NSCLC patients with erlotinib and patritumab, an anti-HER3 monoclonal antibody [86].

**IGF-1R Activation.** IGF-1R has also been proposed to have a role in mediating acquired drug resistance to EGFR TKIs [77, 78], and, in fact, was reported as a biomarker for resistance to the TKI in NSCLC [78]. Unfortunately, data are conflicting: IGF-1R expression has been significantly associated with longer survival in NSCLC patients treated with gefitinib [87]. Further studies are warranted.

**BRAF Mutations.** Mutations occurring in other driver oncogenes may also affect acquired drug resistance to EGFR TKIs. BRAF, but not KRAS, mutations are found for resistance to the TKI in NSCLC [51]. Actually, primary SCLCs are known to have a high prevalence of inactivating mutations in RB1 and TP53 [92]. In contrast, EGFR mutations and gene amplifications are rarely found in sporadic SCLCs [92]. Thus, the loss of RB1 expression can be the most likely scenario for lineage switching [91]. The study also suggested that NSCLC and SCLC may share the same cells of origin [93]. Alveolar type II cells might have the potential [94], but further studies are required.

**EMT** is a cellular mechanism critical for normal development, wound healing and cancer metastasis [95]. In the process of EMT, cells undergo a lineage switch from an epithelial to a mesenchymal phenotype, which causes a loss of cellular polarity, resulting in high motility and increased invasion capability [95]. EMT induction can be triggered by various cell signals, including TGF-beta and Notch-1, and may confer acquired drug resistance [61, 62]. A recent study demonstrated that the mechanisms leading to EMT in TKI-treated patients may involve the activation of AXL RTK [63]. AXL overexpression has been found in 20% of NSCLC samples with progressive disease after treatment with EGFR TKI. However, how EMT promotes TKI drug resistance remains unclear, and additional investigation is warranted.

**Histologic Transformation**

In a rare phenomenon of acquired drug resistance, 2 lineage switches have been reported: histologic transformation of EGFR-mutated NSCLC to SCLC [58–60] and EMT [61–63]. The former has been reported in 2–14% of patients with acquired resistance to EGFR TKI [58–60]. These new SCLCs continued to harbor the initial activating EGFR mutations and were highly sensitive to the chemotherapy regimens for SCLC [60].

The lineage switch from NSCLC adenocarcinoma to SCLC was recently reported to involve the loss of RB1 (retinoblastoma 1) and EGFR proteins [91]. Actually, primary SCLCs are known to have a high prevalence of inactivating mutations in RB1 and TP53 [92]. In contrast, EGFR mutations and gene amplifications are rarely found in sporadic SCLCs [92]. Thus, the loss of RB1 expression can be the most likely scenario for lineage switching [91]. The study also suggested that NSCLC and SCLC may share the same cells of origin [93]. Alveolar type II cells might have the potential [94], but further studies are required.

**Cancer Dormancy and Acquired Drug Resistance**

The origin of resistant cells remains to be elucidated, but they must arise from surviving populations [96–98]. These cells lie temporarily dormant or quiescent as a means of circumventing the effects of the given therapy, but eventually regain their proliferative capacity [99]. The dormant cells resist chemotherapy because they do not divide until the environment is favorable to resume cell proliferation [100]. In the clinical setting, cancer dormancy is observed as a ‘grace period’ after treatment [101]: the signs and symptoms of cancer have disappeared, but the patient occasionally carries surviving tumor cells in local and distant bodily regions.
Drug-Tolerant Persister Cells
In a recent study by Sharma et al. [102], cultured cells from various cancer tissues remained after targeted or cytotoxic chemotherapy. This phenomenon can affect up to 10% of a genetically homogeneous drug-sensitive population; these drug-tolerant cells are thus far more numerous than might be expected from resistance based on the acquisition of de novo genetic mutations. Importantly, however, this was shown to be reversible, which supports the notion of a nonmutational mechanism.

In an analogy to microbial persister cells, these nonmutational drug-resistant cells were defined as drug-tolerant persisters. In 1942, in the study by Hobby et al. [103], Gladys Hobby first described the phenomenon of bacterial persistence, whereby penicillin was found to kill the vast majority of cultured streptococcal cells, but 1% remained intact [104]. These residual cells were characterized in 1944 by Joseph Bigger [105] as 'bacterial persisters'.

In lung cancers, drug-tolerant persisters emerge during treatment as a subset of the cells within primary tumors [96, 102]. Although initially quiescent, persister cells can soon begin to propagate in the presence of EGFR TKIs, becoming drug-tolerant, expanded persisters. These may be cancer stem cells or mesenchymal cells because of their ability to escape the effects of drug treatment by becoming quiescent [102]. Epigenetic mechanisms have been proposed to explain this distinct lineage-switching [102]. However, in our investigation of the small TKI-tolerant subset of NSCLC cells, we could not detect known lung cancer stem cell markers, nor did we uncover expression changes in mesenchymal cell markers [97, 98]. This suggested that a different mechanism could also cause the quiescent status of NSCLC cells after EGFR inhibition.

Drug Resistance of Dormant NSCLC Cells to EGFR TKIs
As mentioned above, we recently studied the mechanism by which a small subset of cells remains viable after EGFR inhibition, despite cell death in the vast majority [96–98, 106, 107]. Our study demonstrated that EGFR inhibition in lung cancer cells generates a drug-tolerant subpopulation by blocking AKT activity and thus inactivating Ets-1 function (fig. 1). The remaining cells enter a dormant, nondividing, quiescent state (G0/G1 arrest) because of the inhibited transactivation of the Ets-1 target genes cyclins D1, D3 and E2. Moreover, Ets-1 inactivation inhibits the transcription of dual-specificity phosphatase 6 (DUSP6), a negative regulator specific for ERK1/2. As a result, ERK1/2 is activated, which then combines with c-Src to renew the activation of the Ras/MAPK pathway, causing increased cell survival by accelerating the turnover of Bim protein. These observations may explain why a small subset of quiescent persister cells can tolerate TKIs, which leads to acquired drug resistance.

Overcoming Drug Resistance to EGFR Inhibitors
Among the numerous therapeutic investigations to improve patient outcomes [2, 8], the focus has narrowed to T790M EGFR, the most common mechanism of drug resistance to gefitinib and erlotinib. Below is an overview of the past decade’s battles to overcome T790M-mediated resistance.

Retreatment with the Same TKI after a Treatment Interruption
Treating patients with other anticancer agents occasionally restores sensitivity to EGFR TKIs (fig. 2a) [108].
Drug Resistance to EGFR Inhibitors in Lung Cancer

Fig. 2. Different strategies to overcome drug resistance to EGFR inhibitors. a Retreatment with the same TKI after a treatment interruption. Resistant tumors are often composed of mixed populations of sensitive and resistant cancer cells. A chemotherapy regimen that interrupts the TKI therapy for a period of time, i.e. a ‘drug holiday’, may effect a restoration of the TKI’s efficacy. b Administration of T790M-specific EGFR TKIs. The third-generation TKIs inhibit both mutations of EGFR activation and resistance. Early-phase studies demonstrated promising response rates in tumors with acquired T790M EGFR mutation. Unfortunately, acquired resistance developed in EGFR with or without the T790M mutation. c Targeting drug-tolerant persister cells. The drug-tolerant persister cells could be a therapeutic target, as reduction of this subset may prevent emergent resistance to EGFR inhibitors. We and other study groups recently proposed a combined EGFR and MEK inhibition therapy.

A chemotherapy regimen that interrupts the TKI therapy for a period of time, i.e. a ‘drug holiday’, may effect a restoration of the TKI’s efficacy [8]. Nevertheless, there is a risk that dormant cancer cells might rapidly expand in some cases when the TKI treatment is suddenly stopped [99, 100].

T790M-Specific EGFR TKIs

In contrast to first-generation reversible EGFR TKIs (gefitinib and erlotinib), second-generation TKIs such as afatinib (Gilotrif) [109], dacomitinib (PF-00299804) [110] and neratinib (HKI-272) [111] bind irreversibly to EGFR and other EGFR family members, including HER2 [8]. These agents were thus thought to be effective for patients with the T790M EGFR drug-resistant mutation [112, 113]. However, early-phase clinical trials found no objective response in this population [114–116].

In contrast, the third-generation TKIs, AZD9291 [117], rociletinib (CO-1686) [118] and WZ4002 [119], inhibit both mutations of EGFR activation and resistance, while they have a modest activity with wild-type EGFR (fig. 2b) [8]. In early-phase studies, AZD9291 and rociletinib demonstrated promising response rates (approx. 60%) in tumors with an acquired T790M EGFR mutation [117, 120, 121]. Unfortunately, acquired resistance to both of these developed in EGFR with or without the T790M mutation, demonstrating intratumor heterogeneity [122–126].

Of the third-site EGFR mutations (i.e. L718Q, L844V and C797S [125]), C797S was found in approximately 40% of AZD9291-resistant T790M-positive tumors. L858R, T790M and C797S EGFR mutation-positive cells showed a partial sensitivity to cetuximab, a monoclonal antibody against EGFR [125]. More recently, additional mechanisms of drug resistance to AZD9291 have been reported, i.e. the loss of the T790M mutation and EGFR gene amplification and also SCLC histologic transformation [122]. These findings suggest that stepwise mono-therapies represent a formidable challenge in drug-resistant cells and that simultaneous multidrug combination therapies should be considered [127].

Targeting Drug-Tolerant Persister Cells

Drug-tolerant persister cells could be a therapeutic target, as reduction of this subset may prevent emergent resistance to EGFR inhibitors (fig. 2c) [97, 98]. Drug-tolerant cells were previously shown to be sensitive to the histone deacetylase (HDAC) inhibitor [102]. However, the combined therapy of erlotinib and entinostat, an HDAC inhibitor, did not improve clinical outcome [128].

Recently, we proposed a combined EGFR and MEK inhibition therapy [96–98, 106, 107]. Our study demon-
stratified that the addition of an MEK inhibitor enhances programmed cell death by rewiring apoptotic signaling after EGFR inhibition in persister cells. Therefore, to decrease the probability of emergent resistance to EGFR TKIs in NSCLCs, combined TKI and MEK inhibitor treatment should be considered. A recent report from another laboratory has also proposed this novel therapy, which is thought to be effective not only in TKI-sensitive activating EGFR mutations but also in the acquired resistance with the T790M second-site EGFR mutation [129]. Interestingly, a separate report showed that ERK1/2 reactivation accompanied DUSP6 reduction after L858R/T790M EGFR-selective inhibition in gefitinib-resistant cells [130]. Thus, a clear rationale for combined treatment exists, regardless of whether the drug resistance is persistent or acquired. A randomized, double-blind trial is necessary before this novel therapy can be integrated into the management of EGFR-mutated NSCLCs in the clinical setting.

Table 1. Mechanisms of drug resistance to EGFR TKIs

<table>
<thead>
<tr>
<th>Primary resistance</th>
<th>Acquired resistance</th>
<th>Persistent resistance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type EGFR [30, 41]</td>
<td>Target alterations</td>
<td>AKT inhibition [96]</td>
</tr>
<tr>
<td>KRAS mutation [31]</td>
<td>T790M EGFR [65]</td>
<td>Epigenetics [102]</td>
</tr>
<tr>
<td>Bim polymorphism [33]</td>
<td>Activation of alternative pathways</td>
<td></td>
</tr>
<tr>
<td>EGFR exon 20 insertions or duplications [45, 46]</td>
<td>MET amplification [50, 81]</td>
<td></td>
</tr>
<tr>
<td>T790M EGFR [47, 48]</td>
<td>HER2 amplification [52, 53]</td>
<td></td>
</tr>
<tr>
<td>Tumor microenvironment [35–37]</td>
<td>HER3 activation [75, 76]</td>
<td></td>
</tr>
<tr>
<td>NF-κB signaling activation [38]</td>
<td>IGF-1R activation [77, 78]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FGF1 activation [79, 80]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BRAF mutation [54]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PTEN loss [55, 56]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NF1 reduction [57]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Histologic transformation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SCLC [58–60]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EMT [61–63]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intratumor heterogeneity</td>
<td>[64]</td>
</tr>
</tbody>
</table>

Table 2. Targeted therapy: EGFR TKIs

<table>
<thead>
<tr>
<th>1st-generation</th>
<th>2nd-generation</th>
<th>3rd-generation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Neratinib [111]</td>
<td>WZ4002 [119]</td>
</tr>
</tbody>
</table>

Conclusions

Over the past decade, EGFR-targeted therapies have dramatically changed the treatment of patients with lung adenocarcinoma. However, drug resistance has become a substantial issue. Recent studies have identified the mechanisms of primary, acquired and persistent drug resistance to TKIs (table 1) and researchers and clinicians have used these findings to develop therapeutic approaches (table 2). However, the stepwise use of single agents presents a formidable challenge. This suggests that researchers and clinicians should consider multidrug combinations to overcome drug resistance. In this era of precision medicine, oncologists must promptly obtain an accurate diagnosis of drug resistance during the individual clinical course to design the most relevant combination to overcome the patient-specific drug resistance in this population [131].

Acknowledgements

This work was supported by grants from the Joan and Irwin Jacobs Fund of the Jewish Community Foundation to O.T. and the National Cancer Institute (1U01CA168370-01) to F.M.
References


Drug Resistance to EGFR Inhibitors in Lung Cancer

DOI: 10.1159/000443368

Chemotherapy 2015–16;61:223–235


